BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12211732)

  • 1. Do fibrinolytic proteins of human bile derive exclusively from gall bladder?
    Gil D; Michalski A; Kondera-Anasz Z; Gil B; Starzewski J; Gonciarz Z
    Med Sci Monit; 2001 May; 7 Suppl 1():262-3. PubMed ID: 12211732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy of t-PA, u-PA, PAI-1 and PAI-2 estimation in human bile by ELISA kits.
    Kondera-Anasz Z; Michalski A; Gil D; Gil B; Starzewski J; Gonciarz Z
    Med Sci Monit; 2000; 6(3):616-7. PubMed ID: 11208381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
    Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
    Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis.
    Kotani I; Sato A; Hayakawa H; Urano T; Takada Y; Takada A
    Thromb Res; 1995 Mar; 77(6):493-504. PubMed ID: 7624837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
    Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
    Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
    Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinolysis and the biliary tree.
    Scott-Coombes DM; Whawell SA; Havranek EG; Thompson JN
    Gut; 1997 Jan; 40(1):92-4. PubMed ID: 9155582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peritoneal fibrinolytic response to various aspects of laparoscopic surgery: a randomized trial.
    Brokelman WJ; Holmdahl L; Bergström M; Falk P; Klinkenbijl JH; Reijnen MM
    J Surg Res; 2006 Dec; 136(2):309-13. PubMed ID: 17054995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasminogen activators and plasminogen activator inhibitors in gingival crevicular fluid of cyclosporin A-treated patients.
    Buduneli N; Buduneli E; Ciotanar S; Atilla G; Lappin D; Kinane D
    J Clin Periodontol; 2004 Jul; 31(7):556-61. PubMed ID: 15191592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
    Steiner E; Pollow K; Hasenclever D; Schormann W; Hermes M; Schmidt M; Puhl A; Brulport M; Bauer A; Petry IB; Koelbl H; Hengstler JG
    Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pro- and antifibrinolytic properties of human pulmonary microvascular versus artery endothelial cells: impact of endotoxin and tumor necrosis factor-alpha.
    Muth H; Maus U; Wygrecka M; Lohmeyer J; Grimminger F; Seeger W; Günther A
    Crit Care Med; 2004 Jan; 32(1):217-26. PubMed ID: 14707582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.
    De Cremoux P; Grandin L; Diéras V; Savignoni A; Degeorges A; Salmon R; Bollet MA; Reyal F; Sigal-Zafrani B; Vincent-Salomon A; Sastre-Garau X; Magdelénat H; Mignot L; Fourquet A;
    Anticancer Res; 2009 May; 29(5):1475-82. PubMed ID: 19443353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasminogen activator in acute myeloid leukaemic marrows: u-PA in contrast to t-PA in normal marrow.
    McWilliam N; Robbie L; Booth N; Bennett B
    Br J Haematol; 1998 Jun; 101(4):626-31. PubMed ID: 9674732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can bile duct injuries be prevented? "A new technique in laparoscopic cholecystectomy".
    Sari YS; Tunali V; Tomaoglu K; Karagöz B; Güneyi A; Karagöz I
    BMC Surg; 2005 Jun; 5():14. PubMed ID: 15963227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue plasminogen activator and plasminogen activator inhibitor-1 in human choledochal bile.
    Lee SJ; Cho JS; Chung JP; Lee KS; Chung JB; Lee SI; Moon YM; Kang JK; Kwon SW; Chi HS; Choi JR; Song KS
    Yonsei Med J; 2000 Feb; 41(1):119-22. PubMed ID: 10731929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urokinase (u-PA) is produced by collecting duct principal cells and is post-transcriptionally regulated by SV40 large-T, arginine vasopressin, and epidermal growth factor.
    Piedagnel R; Tiger Y; Lelongt B; Ronco PM
    J Cell Physiol; 2006 Feb; 206(2):394-401. PubMed ID: 16155905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible role of the plasminogen activation system in human subfertility.
    Ebisch IM; Steegers-Theunissen RP; Sweep FC; Zielhuis GA; Geurts-Moespot A; Thomas CM
    Fertil Steril; 2007 Mar; 87(3):619-26. PubMed ID: 17123524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic architecture of tissue-type plasminogen activator and plasminogen activator inhibitor-1.
    Asselbergs FW; Pattin K; Snieder H; Hillege HL; van Gilst WH; Moore JH
    Semin Thromb Hemost; 2008 Sep; 34(6):562-8. PubMed ID: 19085655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
    Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
    Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of the proteinase specificity in wild-type and stabilized plasminogen activator inhibitor-1: evidence for contribution of intramolecular flexibility.
    De Taeye B; Gils A; Vleugels N; Rabijns A; Declerck PJ
    Biochem Biophys Res Commun; 2004 Aug; 321(3):746-51. PubMed ID: 15358169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.